- ongoing, recruitingTherapeutic use (Phase IV)
Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib - IM011-1115
This study looks at how a new medicine, SOTYKTU, affects certain immune cells (TRM-like cells) in people with plaque psoriasis. Researchers want to see if SOTYKTU helps reduce these cells and their activity over 24 weeks to understand how it treats psoriasis.
Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants with Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, LY4100511, for adults with moderate to severe plaque psoriasis. It's a Phase 2 trial, meaning it's an early stage to see how well the medicine works and if it's safe, compared to a dummy pill.
Hungary · Poland · Czechia - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin
This study is looking at a new treatment for plaque psoriasis. Scientists want to see if it's safe and how it affects the skin. It's a very early-stage study, open to adults with plaque psoriasis, and is designed to understand the treatment better before larger studies begin.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase III, multicentre, randomised, observer-blind, intraindividual, paired, comparative trial to evaluate the efficacy and safety of a 0.1% mometasone furoate cutaneous emulsion compared to Ecural® fat cream and vehicle cutaneous emulsion in the treatment of adult participants with plaque psoriasis
This study is testing a new cream for adults with plaque psoriasis. It compares a new mometasone furoate cream to an existing one and a cream with no medicine, to see how well they reduce psoriasis symptoms and if they are safe.
Poland - completedPhase III
A study comparing JNJ-77242113 and ustekinumab in adult participants with moderate to severe plaque psoriasis
This study compares a new medicine, JNJ-77242113, with an existing one, Stelara, for adults with moderate to severe plaque psoriasis. It aims to see how well the new drug works to reduce red, scaly skin patches by targeting a protein involved in inflammation.
United Kingdom · England · Argentina - recruitingPHASE3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine called deucravacitinib for children and teenagers aged 4 to 17 with moderate to severe plaque psoriasis. It aims to understand how much medicine is needed, if it works, and if it's safe to use.
Argentina · Australia · Brazil - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in Pediatric Subjects with Moderate to Severe Plaque Psoriasis
This study is looking at a new lotion called Duobrii for children and teenagers with moderate to severe plaque psoriasis. Doctors want to see how much of the medicine gets into the body, if it's safe to use every day, and how it affects important body functions.
Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)
This study is looking at a new medicine called BI 765250 for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe, how the body handles it, and if it helps improve psoriasis, compared to a dummy treatment.
Bulgaria · Romania - active not recruitingPHASE3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares how well it works against a dummy treatment (placebo) and an existing medicine called deucravacitinib.
United States · Argentina · Australia - recruitingPHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
This study is looking at a new medicine, JNJ-77242113, for people with plaque psoriasis on sensitive areas like the scalp, genitals, or palms and soles. It aims to see if this medicine works better than a dummy treatment.
United States · Argentina · Canada - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition
This study compares a new version of psoriasis medication from Sun Pharma with the original Sotyktu. It involves healthy adults taking a single dose of each medicine to see if they act the same way in the body after eating.
Romania - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fasting condition.
This study is comparing two versions of a medication for plaque psoriasis called deucravacitinib. We want to see if a new generic version works the same way as the original. Healthy adults take both medicines to help us understand. It's about checking if they are equally effective.
Romania - active not recruitingPHASE3
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares the new medication to a widely used treatment (ustekinumab) and a dummy medicine (placebo) to see how safe and effective it is.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
This study is looking into a new treatment called JNJ-77242113 for moderate to severe plaque psoriasis in teenagers and adults. We want to see how well it works to improve skin symptoms. It's a Phase 3 trial, meaning it's a key step in testing this potential new medicine.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
OptIMMize-1: A Randomized, Active-controlled, Efficacy Assessor-blinded Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
This study is looking at how safe and effective new medicines, risankizumab and ABBV-066, are for young people aged 6 to under 18 with moderate to severe plaque psoriasis, compared to an existing treatment (Stelara).
Germany · Spain · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects with Mild to Moderate Plaque Psoriasis
This study is testing a new medicine, CAN10, for plaque psoriasis. It's the first time CAN10 is being given to people, starting with healthy volunteers and then people with mild to moderate plaque psoriasis, to check if it's safe and how it works.
Germany - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to healthy adult participants
This study looks at how a new medicine, JNJ-81241459, interacts with other common medicines when taken together. It's for healthy adults and helps us understand how drugs might affect each other, which is important for people with skin conditions like plaque psoriasis.
Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Evaluation of Safety, Tolerability, and Pharmacodynamic Effects of Topically Applied SUDO-286 in Psoriasis
This study is testing a new cream called SUDO-286 for plaque psoriasis. We want to see if it's safe to use, how well people tolerate it, and how it affects the body. This is an early study to check its effects in humans.
Germany - ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded-Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy
This study is looking at two medicines, risankizumab and deucravacitinib, for adults with moderate plaque psoriasis. It compares how well they clear up skin and aims to see if switching medicine helps if the first one isn't working as well as hoped.
Hungary · Germany · Greece - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
This study is looking at a new tablet treatment called DC-806 for people with moderate to severe plaque psoriasis. Doctors want to see how well it works to clear skin and if it's safe compared to a dummy pill.
Spain · Poland · Hungary - active not recruitingPHASE2
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
This study looks at a new psoriasis medicine called envudeucitinib. It's for people who have already taken part in an earlier study of this medicine. We want to see how safe and helpful it is over a longer time for widespread plaque psoriasis.
United States · Canada - recruitingPHASE2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, ORKA-001, for people with moderate to severe plaque psoriasis. It aims to find the best dose and see how well it works and if it's safe compared to a dummy treatment.
United States · Canada · Germany - active not recruitingPHASE3
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine called TAK-279 for moderate to severe plaque psoriasis. It aims to see how safe the medicine is and how well people tolerate it, building on earlier studies. It involves participants taking the medicine for up to four years.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
This study is testing a new medicine called JNJ-77242113 for people with moderate to severe plaque psoriasis. Researchers want to see if it works better than a dummy treatment or another existing medicine.
United States · Australia · Brazil - active not recruitingPHASE2
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, ORKA-001, for people in the UK with moderate to severe plaque psoriasis. It compares ORKA-001 to a dummy treatment (placebo) to see if it helps improve skin and is safe. Researchers want to understand how it works over about a year.
United States · Canada - active not recruitingPHASE3
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
This study is looking at a cream called tapinarof for children and teenagers aged 2 to 17 who have a skin condition called plaque psoriasis. It's to see if the cream helps improve their skin over time.
United States · Canada - recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
This study looks at how a treatment called risankizumab affects the quality of life for adults with moderate to severe plaque psoriasis. It's for people already prescribed this medicine by their doctor, and it closely follows their usual care.
Canada · Czechia · France - recruitingPHASE3
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
This study looks at a new medicine called zasocitinib for children and teenagers aged 4-17 with moderate-to-severe plaque psoriasis. It aims to understand how well it works and if it's safe over a long period. Some participants will receive a placebo at first.
United States · China · Germany - active not recruitingPHASE3
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
This study looks at how safe and effective a new medicine, ESK-001, is for people with moderate to severe plaque psoriasis over a long time. It builds on previous studies and carefully watches patients who continue treatment.
United States · Australia · Bulgaria - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-81241459 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis
This study is looking into a new medicine, JNJ-81241459, for people with moderate to severe plaque psoriasis. We want to see how well different doses work to clear up skin patches and if it's safe. It's a key step in developing new treatments.
France · Spain · Poland